论文部分内容阅读
目的:观察应用升血方联合重组人粒细胞刺激因子(G-CSF)治疗化疗后白细胞减少的临床效果。方法:将我院血液科2009年6月到2012年6月收治的80例恶性血液病化疗患者按照随机数字表法分为实验组和对照组,每组40例。实验组给予重组人粒细胞刺激因子和升血方治疗,对照组单纯给予重组人粒细胞刺激因子治疗,观察两组的疗效。结果:实验组和对照组在化疗前差异无统计学意义(P>0.05),治疗7、14、28天检测的白细胞数的变化差异有统计学意义(P<0.05),但实验组效果优于对照组;实验组和对照组重组人粒细胞因子总用量显示,实验组总用量的下降高于对照组的下降水平,但差异无统计学意义(P>0.05)。结论:升血方联合重组人粒细胞刺激因子可有效防治恶性血液病化疗致白细胞减少,提高患者的生活质量。
Objective: To observe the clinical effect of Shengxue Recipe combined with recombinant human granulocyte-stimulating factor (G-CSF) in the treatment of leukopenia after chemotherapy. Methods: Eighty patients with hematologic malignancies admitted to Department of Hematology from June 2009 to June 2012 were divided into experimental group and control group according to random number table method, with 40 cases in each group. The experimental group was treated with recombinant human granulocyte-stimulating factor and Shengxue Recipe. The control group was treated with recombinant human granulocyte-stimulating factor alone, and the curative effect of the two groups was observed. Results: The difference between the experimental group and the control group before chemotherapy was not statistically significant (P> 0.05). The difference of the number of white blood cells detected on the 7, 14 and 28 days was statistically significant (P <0.05) In the control group, the total amount of recombinant human granulocyte cytokines in the experimental group and the control group showed that the decrease of the total amount of experimental group was higher than that of the control group, but the difference was not statistically significant (P> 0.05). Conclusion: Shengxuefang combined with recombinant human granulocyte-stimulating factor can effectively prevent leukopenia caused by chemotherapy of hematologic malignancies and improve the quality of life of patients.